The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included — in one case because of a dosing error. The paper’s author called the findings “hopeful,” but cautioned that it is difficult to interpret the results since they do not include comparison to a control group, as would be the case in a randomized clinical trial. Gilead last month sharply limited its compassionate use program for remdesivir and is conducting its own clinical trials of …read more
Source:: Yahoo Finance
